Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay

Akihiro Muto, Shigehisa Mori, Hiromichi Matsushita, Norihiro Awaya, Hironori Ueno, Nobuyuki Takayama, Shinichiro Okamoto, Masahiro Kizaki, Yasuo Ikeda

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO. The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription-polymerase chain reaction (RT-PCR) remains to be elucidated. We have developed a novel quantitative RT-competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to >0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT-competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.

Original languageEnglish
Pages (from-to)85-94
Number of pages10
JournalBritish Journal of Haematology
Volume95
Issue number1
Publication statusPublished - 1996

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Polymerase Chain Reaction
Recurrence
Genetic Translocation
Gene Fusion
Cytogenetics
Reverse Transcription
Disease Progression

Keywords

  • chemotherapy
  • MAL1/ETO
  • minimal residual disease (MRD)
  • RT-competitive PCR
  • t(8;21)

ASJC Scopus subject areas

  • Hematology

Cite this

Muto, A., Mori, S., Matsushita, H., Awaya, N., Ueno, H., Takayama, N., ... Ikeda, Y. (1996). Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. British Journal of Haematology, 95(1), 85-94.

Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. / Muto, Akihiro; Mori, Shigehisa; Matsushita, Hiromichi; Awaya, Norihiro; Ueno, Hironori; Takayama, Nobuyuki; Okamoto, Shinichiro; Kizaki, Masahiro; Ikeda, Yasuo.

In: British Journal of Haematology, Vol. 95, No. 1, 1996, p. 85-94.

Research output: Contribution to journalArticle

Muto, A, Mori, S, Matsushita, H, Awaya, N, Ueno, H, Takayama, N, Okamoto, S, Kizaki, M & Ikeda, Y 1996, 'Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay', British Journal of Haematology, vol. 95, no. 1, pp. 85-94.
Muto, Akihiro ; Mori, Shigehisa ; Matsushita, Hiromichi ; Awaya, Norihiro ; Ueno, Hironori ; Takayama, Nobuyuki ; Okamoto, Shinichiro ; Kizaki, Masahiro ; Ikeda, Yasuo. / Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. In: British Journal of Haematology. 1996 ; Vol. 95, No. 1. pp. 85-94.
@article{20e0503e70184f8a80f2f8e647d669a5,
title = "Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay",
abstract = "The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO. The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription-polymerase chain reaction (RT-PCR) remains to be elucidated. We have developed a novel quantitative RT-competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to >0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT-competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.",
keywords = "chemotherapy, MAL1/ETO, minimal residual disease (MRD), RT-competitive PCR, t(8;21)",
author = "Akihiro Muto and Shigehisa Mori and Hiromichi Matsushita and Norihiro Awaya and Hironori Ueno and Nobuyuki Takayama and Shinichiro Okamoto and Masahiro Kizaki and Yasuo Ikeda",
year = "1996",
language = "English",
volume = "95",
pages = "85--94",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay

AU - Muto, Akihiro

AU - Mori, Shigehisa

AU - Matsushita, Hiromichi

AU - Awaya, Norihiro

AU - Ueno, Hironori

AU - Takayama, Nobuyuki

AU - Okamoto, Shinichiro

AU - Kizaki, Masahiro

AU - Ikeda, Yasuo

PY - 1996

Y1 - 1996

N2 - The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO. The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription-polymerase chain reaction (RT-PCR) remains to be elucidated. We have developed a novel quantitative RT-competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to >0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT-competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.

AB - The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO. The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription-polymerase chain reaction (RT-PCR) remains to be elucidated. We have developed a novel quantitative RT-competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to >0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT-competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.

KW - chemotherapy

KW - MAL1/ETO

KW - minimal residual disease (MRD)

KW - RT-competitive PCR

KW - t(8;21)

UR - http://www.scopus.com/inward/record.url?scp=0029799137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029799137&partnerID=8YFLogxK

M3 - Article

C2 - 8857943

AN - SCOPUS:0029799137

VL - 95

SP - 85

EP - 94

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -